Search
for
Sort by
Research 91–120 of 138
- Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis
- The most recent advances in understanding and managing hidradenitis suppurativa
- Poster Presentations
- Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
- An evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia
- Discoid lupus erythematosus successfully treated with deucravacitinib
- Alopecia areata after denosumab treatment for osteoporosis
- Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024
- Biologics and Small Molecule Targeted Therapies for Pediatric Alopecia Areata, Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa in the US: A Narrative Review
- Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study
- Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
- Adverse Events in Isotretinoin Therapy: A Single-Arm Meta-Analysis
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
- Baricitinib for the Treatment of Alopecia Areata
- II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata
- Taiwanese Dermatological Association consensus on the diagnosis and management of alopecia areata
- A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions
- Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream
- Teneligliptin-induced hair loss: A case report
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- Adverse Reactions to Biologic Medications Used in Allergy and Immunology Diseases
- Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
- Evaluation of a Combination of Cystine, B Vitamins and Minerals, in the Management of Diffuse Hair Loss in Women: A Prospective, Open-Label Study